Patents Examined by Mark L. Shibuya
-
Patent number: 7713750Abstract: A method for patterning a one or more biomolecules on a substrate that includes coating the substrate with a coating of the one or more biomolecules, applying a laser to the coating, and ablating a portion of the one or more biomolecules with the laser in a predetermined pattern.Type: GrantFiled: May 30, 2007Date of Patent: May 11, 2010Assignee: The Johns Hopkins UniversityInventors: Jan Hoh, William F. Heinz
-
Patent number: 7713752Abstract: Mixing of a sample containing a suspect bioagent or antigen with 1° recognition molecule coated magnetic beads in the preliminary stage of an enzyme linked immunoassay (“ELISA”) procedure is emulated by first inserting the coated magnetic beads into a non-magnetic confinement region, generating a magnetic field B along the axis of said non-magnetic confinement region to agglomerate the coated magnetic beads into a porous mass; then percolating or otherwise forcing the sample solution through said porous mass; and withdrawing the magnetic field to de-agglomerate said coated magnetic beads. In seeping or otherwise flowing through the magnetic beads the molecules of the sample link to respective magnetic beads that are coated with recognition molecules.Type: GrantFiled: February 25, 2003Date of Patent: May 11, 2010Assignee: Northrop Grumman CorporationInventors: Brian M. Sullivan, Denes L. Zsolnay
-
Patent number: 7709271Abstract: The present invention relates to a method and a device for determining a concentration of a biological active substance in a sample by the means of an enzyme-linked immunosorbent assay (ELISA). The device comprises a solid support within a tubing for binding an immunosorbent and an inlet for fluids, a detector for detecting radiation due to an activity in the tubing, wherein the tubing is arranged inside a microchip extending substantially in one plane, for conducting the fluids along the plane of the microchip. The tubing forms a reaction cell having a large detection area. The reaction cell of the microchip is arranged perpendicular to the detector. The method comprises the steps of introducing the fluids into the tubing, conducting the fluids through the tubing forming a reaction cell, in which reaction cell the radiation emitting activity takes place, and detecting the light emitted from the reaction cell substantially perpendicular to the plane.Type: GrantFiled: November 6, 2002Date of Patent: May 4, 2010Assignee: Prolight Diagnostics ABInventor: Masoud Khayyami
-
Patent number: 7709273Abstract: Methods, compositions and kits are disclosed. The compositions are light emitting and comprise a polymeric matrix having dissolved therein a photoactive compound. The composition has the characteristic that, after activation of the photoactive compound, the rate of decrease in the intensity of light emission at any time during a 20-fold decrease in the intensity is proportional to the intensity of the light emission. In one embodiment the polymeric matrix is comprised of particles of about 20 nm to about 100 ?m in diameter to which is bound a specific binding pair member. The particles generally comprise a polymeric matrix having dissolved therein about 1 to about 20% by weight of a dopant. The compositions may be used in methods for determining an analyte. A combination is provided comprising (1) a medium suspected of containing the analyte, (2) and the aforementioned composition. The photoactive substance is activated and the effect of the activating on the optical properties of the combination is detected.Type: GrantFiled: November 14, 2005Date of Patent: May 4, 2010Assignee: Siemens Healthcare Diagnostics Products GmbHInventors: Sharat Singh, John S. Pease, Jacqueline Sadakian, Daniel B. Wagner, Edwin F. Ullman
-
Patent number: 7700372Abstract: A rapid assay concentration device. In one form, the device includes a substrate and a plurality of elongated membranes on the substrate. At least one capture zone is formed in each membrane. Each capture zone is responsive to the presence of a target chemical in the fluid. Capture zones on different membranes have different threshold levels of response to the chemical. In a method for monitoring temporal changes of analyte levels in a source multiple test devices are provided, with each device including a plurality of regions. Each region is responsive at a different sensitivity level to indicate presence of the analyte. A source sample is brought into contact with a first of the test devices to determine whether the source contains a level of analyte sufficient to induce a response thereto in one or more of the test unit regions.Type: GrantFiled: October 8, 2003Date of Patent: April 20, 2010Inventor: Tara Nylese
-
Patent number: 7696329Abstract: The present invention is related to immunoglobulin peptides that recognize a thermostable antigen from bovine blood. The invention also provides methods for determining the presence of bovine blood in a food sample or an animal feed sample.Type: GrantFiled: December 27, 2006Date of Patent: April 13, 2010Assignee: Florida State University Research Foundation, Inc.Inventor: Yun-Hwa Peggy Hsieh
-
Patent number: 7682837Abstract: The invention includes devices and methods for forming random arrays of magnetic particles, arrays formed using these devices and methods, and to methods of using the arrays. The invention provides an assembly (chip) with magnetic domains that produce localized magnetic fields capable of immobilizing magnetic particles such as commercially available magnetic beads. Probe or sensor molecules can be coupled to the beads, which are then dispersed on the assembly, forming a random order array. The arrays can be used for analyzing samples, targets, and/or the interaction between samples and targets. The invention finds particular use in processes such as high-throughput genotyping and other nucleic acid hybridization-based assays.Type: GrantFiled: August 7, 2001Date of Patent: March 23, 2010Assignee: Board of Trustees of Leland Stanford Junior UniversityInventors: Maneesh Jain, Robert L. White, Lester A. Roberts
-
Patent number: 7682838Abstract: Magnetic nanoparticles and methods for their use in detecting biological molecules are disclosed. The magnetic nanoparticles can be attached to nucleic acid molecules, which are then captured by a complementary sequence attached to a detector, such as a spin valve detector or a magnetic tunnel junction detector. The detection of the bound magnetic nanoparticle can be achieved with high specificity and sensitivity.Type: GrantFiled: November 9, 2007Date of Patent: March 23, 2010Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Shan X. Wang, Robert L. White, Chris D. Webb, Guanxiong Li
-
Patent number: 7674632Abstract: A method and composition for detecting and measuring analytes, such as antibodies, which are capable of binding with certain binding partners such as antigens. A homogenous assay is performed in the presence of free unbound antibodies. Such a homogeneous assay testing for specific antibodies is herein possible by defining of test subsets of microparticles having specific antigens thereon which are capable of binding with specific target antibodies. The microparticle suspension also includes at least two calibration subsets of microparticles having a binding partner thereon with at least two known levels of concentration which is capable of binding with human antibodies for the purpose of assay calibration. A verification subset of microparticles is included with another binding partner thereon at a known concentration, capable of binding with anti-human antibodies. This suspension is incubated with a human sample and then is incubated with a tagging component.Type: GrantFiled: November 15, 2002Date of Patent: March 9, 2010Assignee: Zeus Scientific, IncInventors: Mark Carle Connelly, Mark Kopnitsky
-
Patent number: 7655184Abstract: A self-contained apparatus using a gravitationally encouraged, interrupted, downward, diffusive and programmed flow of fluid to provide for rapid confirmatory immunological testing (“RCIT”) in, for example, a clinical, point-of-care setting. A fluid specimen such as blood, saliva or urine is deposited into a first chamber carrying a source of conjugate having mobilizable binding members such as immunographic antigens or antibodies specific to the condition being tested conjugated to a detectable label such as colloidal gold. The specimen is premixed with a first measured, reactive mix buffer solution carried within an openable tank. The specimen and solution are temporarily held within an incubation reservoir formed behind a dam made from porous, diffusive material.Type: GrantFiled: April 20, 2007Date of Patent: February 2, 2010Assignee: DNT Scientific Research, LLCInventors: Naishu Wang, David F. Zhou
-
Patent number: 7651868Abstract: A system for the rapid characterization of analytes in saliva. In one embodiment, a system for detecting analytes includes a light source, a sensor array, and a detector. The sensor array is formed from a supporting member, in which a plurality of cavities may be formed. A series of chemically sensitive particles, in one embodiment, are positioned within the cavities. The particles may produce a signal when a receptor, coupled to the particle, interacts with the cardiovascular risk factor analyte and the particle-analyte complex is visualized using a visualization reagent. Using pattern recognition techniques, the analytes within a multi-analyte fluid may be characterized. In an embodiment, each cavity of the plurality of cavities is designed to capture and contain a specific size particle. Flexible projections may be positioned over each of the cavities to provide retention of the particles in the cavities.Type: GrantFiled: December 13, 2004Date of Patent: January 26, 2010Assignee: The Board of Regents of The University of Texas SystemInventors: John T. McDevitt, Eric V. Anslyn, Jason B. Shear, Dean P. Neikirk, Nick J. Christodoulides
-
Patent number: 7651841Abstract: A flow-through assay for detecting the quantity of an analyte residing in a test sample is provided. The flow-through assay contains a porous membrane that is in fluid communication with probe conjugates that contain a specific binding member and a detectable probe. The porous membrane also defines a detection zone and a calibration zone. The calibration zone contains a polyelectrolyte substantially non-diffusively immobilized on the porous membrane. The polyelectrolyte is capable of generating a detectable calibration signal that can be readily compared (visually, quantitatively, and the like) to a detection signal to determine the amount of analyte in the test sample.Type: GrantFiled: April 25, 2002Date of Patent: January 26, 2010Assignee: Kimberly-Clark Worldwide, Inc.Inventors: Xuedong Song, Ning Wei, Curt Sayre
-
Patent number: 7632461Abstract: An automated in situ heat induced antigen recovery and staining method and apparatus for treating a plurality of microscope slides. The process of heat induced antigen recovery and the process of staining the biological sample on the microscope slide are conducted in the same apparatus, wherein the microscope slides do not need to be physically removed from one apparatus to another. Each treatment step occurs within the same reaction compartment. The reaction conditions of each reaction compartment for treating a slide can preferably be controlled independently, including the individualized application of reagents to each slide and the individualized treatment of each slide. The reagents are preferably held in a reagent dispensing strip similar to a “blister pack”.Type: GrantFiled: September 17, 2004Date of Patent: December 15, 2009Inventor: Lee Angros
-
Patent number: 7622077Abstract: An automated in situ heat induced antigen recovery and staining method and apparatus for treating a plurality of microscope slides. The process of heat induced antigen recovery and the process of staining the biological sample on the microscope slide are conducted in the same apparatus, wherein the microscope slides do not need to be physically removed from one apparatus to another. Each treatment step occurs within the same reaction compartment. The reaction conditions of each reaction compartment for treating a slide can preferably be controlled independently, including the individualized application of reagents to each slide and the individualized treatment of each slide. The reagents are preferably held in a reagent dispensing strip similar to a “blister pack”.Type: GrantFiled: September 17, 2004Date of Patent: November 24, 2009Inventor: Lee Angros
-
Patent number: 7615382Abstract: The present invention provides a magnetic sifter that is small in scale, enables three-dimensional flow in a direction normal to the substrate, allows relatively higher capture rates and higher flow rates, and provides a relatively easy method of releasing captured biomolecules. The magnetic sifter includes at least one substrate. Each substrate contains a plurality of slits, each of which extends through the substrate. The sifter also includes a plurality of magnets attached to the bottom surface of the substrate. These magnets are located proximal to the openings of the slits. An electromagnetic source controls the magnitude and direction of magnetic field gradient generated by the magnets. Either one device may be used, or multiple devices may be used in series. In addition, the magnetic sifter may be used in connection with a detection chamber.Type: GrantFiled: November 9, 2006Date of Patent: November 10, 2009Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Shan X. Wang, Nader Pourmand, Robert L. White
-
Patent number: 7615376Abstract: In a process for the quantitative optical analysis of fluorescently labelled biological cells 5, a cell layer on a transparent support at the bottom 2 of a reaction vessel 1 is in contact with a solution 3 containing the fluorescent dye 4. The sensitivity of analytical detection can be considerably improved if to the fluorescent dye 4 already present in addition a masking dye 9, which absorbs the excitation light 6 for the fluorescent dye 4 and/or its emission light 7, is added to the solution 3 and/or if a separating layer 10 permeable to the solution and absorbing and/or reflecting the excitation light 6 or the emission light 7 is applied to the cell layer at the bottom 2. This process can also be used for improving the sensitivity in the quantitative optical analysis of a luminescent biological cell layer. The separating layer 10 must in this case be composed such that it has a high power of reflection for the luminescent light 11.Type: GrantFiled: August 27, 2008Date of Patent: November 10, 2009Assignee: Bayer Schering Pharma AktiengesellschaftInventors: Thomas Krahn, Wolfgang Paffhausen, Andreas Schade, Martin Bechem, Delf Schmidt
-
Patent number: 7611480Abstract: An in-vivo bioreactor device producing a dialysis effect by acting within the gastrointestinal tract for the removal of undesirable concentrated intestinal or blood substances or metabolites is disclosed. The ingestible device is comprised of a body wall that surrounds an internal compartment. Along the wall of the shell are openings located around the periphery that allow bodily fluids to enter and exit device. The wall of the device is comprised in whole or at least in part of materials that are impermeable to the passage of external fluids and maintains its physical and chemical integrity in the environment of use during its activity. Semi-permeable membranes located either internally or externally of the device are able to withstand all physiological temperatures and pH and act in a similar manner to dialysis membranes that are used for the separation of substances in suspensions, solutions, tissue cultures, etc.Type: GrantFiled: April 24, 2003Date of Patent: November 3, 2009Inventor: Mark M. Levy
-
Patent number: 7611853Abstract: Malarial parasite Plasmodium falciparum is responsible for the most severe form of malaria in humans, causing about 2 million deaths every year. Lack of effective vaccines and emergence of drug-resistant strains necessitate the need of novel drug targets to treat the disease. The present invention describes a novel assay method of identifying candidate compounds as anti-malarials based on the property of binding to plasmodial parasite 90 kDa heat shock protein.Type: GrantFiled: December 1, 2003Date of Patent: November 3, 2009Assignee: Indian Institute of ScienceInventors: Tatu Utpal, Pavithra Soundara Raghavan, Banumathy Gowrishankar
-
Patent number: 7585682Abstract: The invention involves methods, assays, and components for the detection and analysis of binding between biological or chemical species, and can specifically be used for drug discovery. In an example where drug discovery is carried out, different candidate drugs can be attached to different articles such as magnetic beads. The beads can be exposed to colloid particles carrying signaling entities, or other signaling entities, immobilized with respect to protein targets of the drug candidates. After incubation, all beads are drawn to separate surface locations magnetically. Beads are released from surface locations where it is determined that signaling entities do not exist, and are removed from the assay. Beads held at other surface locations then are released, re-distributed, and re-attracted to surface locations. This is repeated with appropriate wash steps, until individual drug candidates can be isolated and identified.Type: GrantFiled: October 3, 2001Date of Patent: September 8, 2009Assignee: Minerva Biotechologies CorporationInventor: Cynthia C. Bamdad
-
Patent number: 7569353Abstract: The present invention relates to the diagnosis of hematopoietic disorders and to determining the prognosis of patients affected by such disorders. The methods generally comprise determining a level of myeloperoxidase in a body fluid sample from the individual and using the level as a factor for diagnosing the disorder in the mammal or as a factor for determining the prognosis of a patient diagnosed with such a disorder. Myelodysplastic syndrome, acute myeloid leukemia and chronic myeloid leukemia are exemplary disorders. Also provided are method of cancer therapy involving reducing the level of myeloperoxidase in the body fluid of the individual.Type: GrantFiled: November 4, 2004Date of Patent: August 4, 2009Assignee: Quest Diagnostics Investments IncorporatedInventor: Maher Albitar